Proteinuria
Gain insight into target proteinuria thresholds and their relevance in IgAN management from Dr Colbert. Learn more about IgAN pathophysiology: References: Read More
- About
- IgAN
- Events
- Resource Center
- Simulators
What interests you?+Help Us Enhance Your NephU ExperienceHelp Us Enhance Your NephU Experience
User experience form
IgA Nephropathy
4-Hit Process
Join Dr Lerma as he outlines the role of the 4-hit process in IgAN pathogenesis. Learn more about IgAN pathophysiology: References: Read MoreCurrent Management
Learn about the current strategies for the management of IgAN and the ongoing need for therapies that target the underlying causes of IgAN. Hear more from our experts: References: Read MoreUrgency to Treat
Explore how early detection and diagnosis of IgAN can support timely treatment and help reduce the risk of disease progression. Hear more from our experts: Reference: Read MorePathophysiology
Explore the role of APRIL in B-cell development and IgAN pathogenesis, and learn how a better understanding of IgAN pathophysiology allows for a more targeted management approach. Hear more from… Read MoreDisease Burden
Discover how the burden of IgAN, including the likelihood of progression to kidney failure within 10–15 years, can significantly affect patients’ mental and emotional well-being. Hear more from our experts:… Read MoreKey Messages from KDIGO IgAN Experts (2025)
These videos are part of a three-part series featuring IgA Nephropathy (IgAN) experts and Work Group Members of the forthcoming KDIGO 2025 IgAN Guideline Update sharing key insights on emerging… Read MoreIgA Nephropathy: Pathogenesis, the Role of APRIL & the 4-Hit Process, & a Patient Case Study
The goal of this event is to provide a detailed overview of the Four-Hit hypothesis as well as explain the role of APRIL in disease pathogenesis. Read MoreA Targeted Approach for Immunoglobulin-A Nephropathy
Dr. Srinivasan will discuss the four hit pathogenic process of IgA nephropathy, including the role of galactose deficient immunoglobulin-A1 (Gd-IgA1) and A-proliferation inducing ligand (APRIL). Additional pathways in the disease… Read MoreNephU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc. (OAPI) - committed supporters of the kidney health community. The information provided through NephU is intended for the educational benefit of health care professionals and others who support care for those with kidney disease and other related conditions. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing NephU’s educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by NephU. Some of the contributors may be paid consultants of OPDC and/or OAPI.©2025 Otsuka Pharmaceutical Development & Commercialization, Inc. All rights reserved. - IgAN
